Trial Profile

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Prednisone; Procarbazine
Indications Hodgkin's disease
Focus Therapeutic Use

Most Recent Events

01 Feb 2022 Results published in the Leukemia
17 Jun 2021 Results of follow-up analysis of this randomized phase II study, presented at the 26th Congress of the European Haematology Association
26 Oct 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com